Hologic, Inc. with ticker code (HOLX) now have 14 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $95.00 and $75.00 and has a mean share price target at $83.07. (at the time of writing). Given that the stocks previous close was at $74.98 and the analysts are correct then there would likely be a percentage uptick in value of 10.8%. The 50 day MA is $71.74 and the 200 moving average now moves to $75.14. The market capitalization for the company is 17.61B. The current share price for the company is: $75.05 USD
The potential market cap would be $19,515,176,050 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 41.01, revenue per share of $16.33 and a 6.58% return on assets.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products focused on women’s health and well-being through early detection and treatment. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics segment offers a range of diagnostics products, such as ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. Its Breast Health segment offers a portfolio of solutions for breast cancer care, primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment offers a range of products, such as NovaSure Endometrial Ablation System, MyoSure Hysteroscopic Tissue Removal System and Fluent Fluid Management system as well as its Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, and the Fluoroscan Insight FD mini C-arm.
